Mocroft A,Ledergerber B,Katlama C,et al. Decline in the AIDS and death rates in the EuroSIDA study: an observation study[J].Lancet,2003,362(9377): 22.
[2]
Fujie Zhang, Zhihui Dou, Ye Ma, et al. Five-year outcomes of the China national free antiretroviral treatment program[J].Annals Int Med,2009, 151:241.
[3]
Moore R D,Chaisson R E.Natural history of HIV infection in the era of combination antiretroviral therapy[J].AIDS,1999,13 (14):1933.
[4]
Sabin C A, H ill T, Lampe F, et al. Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study [J]. Bri Med J, 2005, 300: 695.
[5]
World Health Organization. The HIV drug resistance report [EB/OL]. 2012-05-01. http://www.who.int/about/licensing/copyright_form/en/index.html.
[6]
Roberts L, Passmore J A, Willianson C, et al. Plasma cytokine level during acute HIV-1 infection predict HIV disease progression[J]. AIDS, 2010,24:819.
[7]
Frentz D, Boucher C A, van de Vijver D A. Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world[J]. AIDS Reviews, 2012, 14:17.
[8]
Art F Y Poon, Jeannette L Aldous, W Christopher Mathews, et al. Transmitted drug resistance in the CFAR network of integrated clinical systems cohort: prevalence and effects on pre-therapy CD4 and viral load[J]. PLoS ONE, 2011, 6:e21189.
[9]
Li X P, Xing H, Wang Z, et al. Study of HIV-1 drug resistance in patients receiving free antiretroviral therapy in China[J]. Virol Sin, 2007,22:233.
[10]
Dongbao Yu, Donald Sutherland, Massimo Ghidinellil,et al. Systematic review of HIV drug resistance assessment in the western pacific region[J]. AIDS Reviews,2011,13:12.
Zhang F,Haberer J,Wei H,et al. Drug resistance in the Chinese national pediatric highly activeantiretroviral therapy cohort: impli-cations for paediatric treatment in the developing world[J].Int J STD AIDS,2009,20(6):406.
[16]
Liu L,Lu H Z,Henry M,et al. Polymorphism and drug selected mu-tations of reverse transcriptase gene in 102 HIV-1 infected patients living in China[J].J Med Virol,2007,79(10): 1593.
[17]
Zhong P,Kang L Y,Pan Q C,et al. Identification and distribution of HIV type 1 genetic diversity and protease inhibitor resistance-asso-ciated mutations in Shanghai,China[J].J Acquir Immune Defic Syndr,2003,34(1): 91.
[18]
Ren J, Nichols C E, St amp A, et al. Structural insights into mechanisms of non-nucleoside drug resist ance for HIV- 1 reverse transcriptases mutated at codons 101 or 138[J]. FEBS J, 2006, 273(16): 3850.
[19]
Clark S A, Shulman N S, Bosch R J, et al.Reverse transcriptase mutations 1181, 208Y, and 215Y cause H IV-1 hyper susceptibility to nonnucleoside reverse transcriptase inhibitors[J]. AIDS, 2006, 20(7): 981.
[20]
Prabu-Jeyabalan M, King N, Nalivaika E, et al.Drug resistance and subsetrate recognition in HIV-1 protease[J].Antiviral Ther, 2002, 7(S1): S361.
[21]
Developed by the DHHS panel on antiretroviral guidelines for adults and adolescents-A working group of the office of AIDS research advisory council (OARAC):guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents[EB/OL].[2008-11-03].http://aidsinfo.nih.gov/guidelines.
